Here’s why Citi says crypto prices have been weak recently
Investing.com - Jefferies raised its price target on EDAP TMS S.A. (NASDAQ:EDAP) to $2.00 from $1.80 while maintaining a Hold rating on the medical device company’s stock. The micro-cap company, currently valued at approximately $78 million with shares trading at $2.00, has seen its stock price decline 26.6% over the past year.
The price target increase follows EDAP’s third-quarter sales of $16 million, representing 12% growth and exceeding consensus estimates of $15 million. The company reported eight Focal One placements during the quarter, surpassing Jefferies’ expectation of more than four units.
EDAP’s U.S. HIFU procedure growth accelerated to 15% compared to 5% in the previous quarter, while HIFU treatment-driven sales grew 26% year-over-year. The company secured a €36 million credit facility after the third quarter ended. Despite this growth, InvestingPro data shows EDAP is not profitable, with a negative EPS of -$0.66 over the last twelve months and an EBITDA of -$21.73 million.
The medical technology firm reaffirmed its fiscal year 2025 guidance for HIFU sales growth between 26% and 34%. Jefferies raised its estimates based on the third-quarter performance beat. However, analysts expect the company’s net income to drop this year, with EPS forecasts for FY2025 at -$0.82.
Jefferies noted there was no change to the capital expenditure environment for EDAP, which specializes in high-intensity focused ultrasound technology for minimally invasive treatments. Interestingly, with a beta of -0.14, EDAP’s stock price often moves in the opposite direction of the broader market. InvestingPro offers additional insights with 8 more ProTips and comprehensive financial health metrics in its Pro Research Report, available for over 1,400 US equities.
In other recent news, EDAP TMS SA reported its third-quarter 2025 earnings, revealing a net loss of €0.13 per share. This result exceeded analyst expectations, which had forecast a loss of -$0.2108 per share. The company also announced revenue of €13.9 million, reflecting a 6% increase compared to the previous year. These financial results indicate improved performance, contributing to positive investor sentiment. Additionally, strategic growth initiatives were noted as a factor in the company’s recent developments. The earnings report highlights the company’s efforts in enhancing its financial standing. Analyst firms had not provided any upgrades or downgrades in the recent articles. These developments are part of the ongoing efforts by EDAP TMS to strengthen its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.